# A Study of SHR6390 in Advanced Solid Tumor Patients

> **NCT02684266** · PHASE1 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 40 (actual)

## Conditions studied

- Neoplasm

## Interventions

- **DRUG:** SHR6390

## Key facts

- **NCT ID:** NCT02684266
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-03
- **Primary completion:** 2019-06-28
- **Final completion:** 2019-06-28
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2022-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02684266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02684266, "A Study of SHR6390 in Advanced Solid Tumor Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02684266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*